DNMT3a knockout CAR T cells with antigen specificity (for solid tumors) (SJ-19-0024)

St. Jude Reference #SJ-19-0024


Researchers at St. Jude have invented a cell therapy that consists of tumor-specific T cells in which DMNT3a is knocked out and the STAT5 pathway is activated by IL15. This is useful in developing immunotherapies for cancer and other diseases targeting defined antigens (pediatrics as well as adult). The researcher’s results indicate effector function was dramatically improved and development continues.


T cell therapy, solid tumor, DMNT3 knockout, STAT5 pathway, IL15

Granted patents or published applications

Pending US application and international application published as WO 2020/210365 A1 

Related scientific references

Knocking out specific gene prevents T-cell exhaustion, boosts CAR T-cell responses

Brooke Prinzing et al, Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity, Science Translational Medicine (2021). DOI: 10.1126/scitranslmed.abh0272

Licensing opportunities

St. Jude is seeking a partner or partners to help develop this for use with therapies. 
Contact: chad.riggs@stjude.org

Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.